The role of long non-coding RNA (lncRNA) in idiopathic pulmonary fibrosis (IPF) is poorly
understood. We found a novel lncRNA-ITPF that was upregulated in IPF. Bioinformatics and …

Background With the rapid advances of genetic and genomic technologies, the
pathophysiological mechanisms of idiopathic pulmonary fibrosis (IPF) were gradually …

Background Idiopathic pulmonary fibrosis (IPF) has high mortality worldwide. The CD247
molecule (CD247, as known as T-cell surface glycoprotein CD3 zeta chain) has been …

Background Routinely-collected healthcare data provide a valuable resource for
epidemiological research. Validation studies have shown that for most conditions, simple …

There is growing evidence of the role of infection in the pathogenesis and progression of
idiopathic pulmonary fibrosis (IPF)[1–4]. Over a third of patients with IPF will be hospitalised …

Background and objective Antifibrotic therapy with nintedanib or pirfenidone slows disease
progression and reduces mortality in patients with idiopathic pulmonary fibrosis (IPF) …

IPF clinical trial design and endpoints : Current Opinion in Pulmonary Medicine IPF clinical trial
design and endpoints : Current Opinion in Pulmonary Medicine Log in or Register Subscribe to …

Abstract Background The FinnishIPF registry is a prospective, longitudinal national registry
study on the epidemiology of idiopathic pulmonary fibrosis (IPF). It was designed to describe …

Background Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are
scarce, outside of registries. In France, pirfenidone and nintedanib are only reimbursed for …

Major risk factors for idiopathic pulmonary fibrosis (IPF) include older age and a history of
smoking, which predispose to several pulmonary and extra-pulmonary diseases. IPF can be …